BCR-ABL Truncation due to Premature Translation Termination as a Mechanism of Resistance to Kinase Inhibitors
Open Access
- 31 March 2009
- journal article
- review article
- Published by S. Karger AG in Acta Haematologica
- Vol. 121 (1), 27-31
- https://doi.org/10.1159/000210060
Abstract
The Philadelphia (Ph) chromosome, a shortened version of chromosome 22, results from a reciprocal translocation between chromosomes 9q34 and 22q11 [1,2,3]. The Ph translocation positions the c-ABL gene of chromosome 9 downstream from the breakpoint cluster region (BCR) on chromosome 22; the resulting fusion gene produces a 190- or 210-kDa hybrid protein with constitutive kinase activity associated with chronic myelogenous leukemia (CML). The impressive clinical efficacy of imatinib mesylate, a selective and effective ABL kinase inhibitor, has revolutionized the treatment of CML. However, the development of resistance to imatinib, which occurs over months to years, constitutes a major drawback in the treatment of advanced CML [4, 5]. Mechanisms leading to drug resistance include amplification of the BCR-ABL gene, acquired additional genomic alterations, and most importantly, specific mutations within the ABL kinase domain that impede drug binding [2, 3,6,7,8].Keywords
This publication has 24 references indexed in Scilit:
- Characterization of BCR-ABL deletion mutants from patients with chronic myeloid leukemiaLeukemia, 2008
- The BCR-ABL Story: Bench to Bedside and BackAnnual Review of Immunology, 2004
- Localization of BCR-ABL to F-actin regulates cell adhesion but does not attenuate CML developmentBlood, 2003
- Detection of BCR-ABL mutations in patients with CML treated with imatinib is virtually always accompanied by clinical resistance, and mutations in the ATP phosphate-binding loop (P-loop) are associated with a poor prognosisBlood, 2003
- Mechanisms of Autoinhibition and STI-571/Imatinib Resistance Revealed by Mutagenesis of BCR-ABLCell, 2003
- Homo- and hetero-oligomerization of the c-Abl kinase and Abelson-interactor-1.2003
- STI571 (Gleevec™) as a paradigm for cancer therapyTrends in Molecular Medicine, 2002
- BCR-ABL gene mutations in relation to clinical resistance of Philadelphia-chromosome-positive leukaemia to STI571: a prospective studyThe Lancet, 2002
- Roots of clinical resistance to STI-571 cancer therapy.2001
- Deletion of the Src Homology 3 Domain and C-terminal Proline-rich Sequences in Bcr-Abl Prevents Abl Interactor 2 Degradation and Spontaneous Cell Migration and Impairs LeukemogenesisJournal of Biological Chemistry, 2001